Capstone Therapeutics (CAPS) Competitors $1.02 -0.08 (-7.27%) As of 10/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPS vs. RANI, SCYX, IMA, XCUR, KZR, AKTX, RNTX, SONN, DARE, and ENLVShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Rani Therapeutics (RANI), SCYNEXIS (SCYX), ImageneBio (IMA), Exicure (XCUR), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), Rein Therapeutics (RNTX), Sonnet BioTherapeutics (SONN), Dare Bioscience (DARE), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors Rani Therapeutics SCYNEXIS ImageneBio Exicure Kezar Life Sciences Akari Therapeutics Rein Therapeutics Sonnet BioTherapeutics Dare Bioscience Enlivex Therapeutics Capstone Therapeutics (NASDAQ:CAPS) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Is CAPS or RANI more profitable? Capstone Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capstone TherapeuticsN/A N/A N/A Rani Therapeutics N/A -1,258.76%-97.97% Which has more risk & volatility, CAPS or RANI? Capstone Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Does the media favor CAPS or RANI? In the previous week, Rani Therapeutics had 15 more articles in the media than Capstone Therapeutics. MarketBeat recorded 16 mentions for Rani Therapeutics and 1 mentions for Capstone Therapeutics. Rani Therapeutics' average media sentiment score of 0.16 beat Capstone Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Capstone Therapeutics Neutral Rani Therapeutics Neutral Which has preferable valuation & earnings, CAPS or RANI? Capstone Therapeutics has higher revenue and earnings than Rani Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstone Therapeutics$44.88M0.17-$2.56MN/AN/ARani Therapeutics$1.20M98.22-$30.02M-$0.91-1.80 Do insiders and institutionals have more ownership in CAPS or RANI? 2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate CAPS or RANI? Rani Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 347.15%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Capstone Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryRani Therapeutics beats Capstone Therapeutics on 8 of the 13 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.02M$3.40B$6.10B$10.50BDividend YieldN/A2.28%5.73%4.81%P/E RatioN/A22.4484.5227.09Price / Sales0.17429.40586.66210.72Price / CashN/A46.5937.1661.22Price / Book-0.0510.4112.246.52Net Income-$2.56M-$52.47M$3.32B$276.75M7 Day Performance-9.73%2.32%1.25%2.00%1 Month Performance-32.89%11.14%6.28%2.26%1 Year PerformanceN/A11.15%59.92%35.58% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.02-7.3%N/AN/A$8.02M$44.88M0.0038Analyst ForecastRANIRani Therapeutics2.5899 of 5 stars$0.46-4.0%$7.33+1,500.5%-37.6%$32.93M$1.20M-0.50110Trending NewsShort Interest ↑Gap UpHigh Trading VolumeSCYXSCYNEXIS0.6626 of 5 stars$0.77-2.7%N/A-50.0%$32.28M$3.75M-1.9260News CoverageAnalyst ForecastShort Interest ↑Gap DownIMAImageneBio2.8337 of 5 stars$7.96-3.3%$35.50+346.0%-63.3%$31.88M$3.50M-1.0470Negative NewsShort Interest ↑XCURExicure1.159 of 5 stars$4.95-12.9%N/A+56.0%$31.27M$500K-1.2850Gap UpKZRKezar Life Sciences2.3194 of 5 stars$4.22-4.1%$9.00+113.3%-22.1%$30.90M$7M-0.4460News CoverageAnalyst ForecastGap UpAKTXAkari Therapeutics2.641 of 5 stars$0.93-8.8%$3.30+254.8%-65.7%$30.33MN/A0.009News CoverageShort Interest ↑Gap UpRNTXRein Therapeutics2.608 of 5 stars$1.30-5.1%$10.00+669.2%N/A$30.30MN/A-0.489SONNSonnet BioTherapeutics1.6922 of 5 stars$4.41-7.0%$20.00+353.5%-40.6%$30.11M$20K0.0010News CoverageDAREDare Bioscience2.5262 of 5 stars$2.12-4.9%$10.00+371.7%-43.6%$28.58M$10K-0.9930Positive NewsENLVEnlivex Therapeutics2.6882 of 5 stars$1.15-2.1%$10.00+769.6%-35.0%$27.94MN/A-1.9870News Coverage Related Companies and Tools Related Companies RANI Alternatives SCYX Alternatives IMA Alternatives XCUR Alternatives KZR Alternatives AKTX Alternatives RNTX Alternatives SONN Alternatives DARE Alternatives ENLV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
